Guardant tests for cancer screening, recurrence monitoring and treatment selection will be available to patients through Bayshore HealthCare providers
Guardant Health, Inc, a leading precision oncology company, announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant’s portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinics in Canada.
Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding Quebec), and the agreement will significantly expand access to advanced cancer testing tools for its providers and patients. Bayshore’s clinics will offer Guardant360® tests to inform therapy selection in advanced cancer, the Guardant Reveal™ blood test for minimal residual disease (MRD) detection and recurrence monitoring in early-stage cancer, and the Shield™ blood test for colorectal cancer screening.
Also Read: TRIMEDX appoints Neil de Crescenzo as CEO
“Guardant Health is proud to partner with Bayshore HealthCare in fulfilling their mission to provide better outcomes for patients,” said Helmy Eltoukhy, Guardant chairman and co-CEO. “This partnership will give their physicians access to the latest molecular profiling technology to provide a more complete view of cancer, helping them to develop optimal personalized care plans for their patients, improve outcomes and reduce the number of lives lost to cancer.”
“Providing customized care plans for our clients is central to Bayshore Healthcare’s mission,” said Karl Frank, Divisional Director, Bayshore Specialty Rx. “This partnership will enable our healthcare providers to utilize Guardant’s precision oncology testing to help detect cancer earlier, develop a targeted treatment program for each individual, and better monitor each patient’s response to therapy, with the goal of elevating our care for patients living with cancer.”
Source: Businesswire